Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT02337491 |
Title | Pembrolizumab +/- Bevacizumab for Recurrent GBM |
Recruitment | Completed |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Dana-Farber Cancer Institute |
Indications | |
Therapies | |
Age Groups: | adult |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
University of California, Los Angeles | Los Angeles | California | 90095 | United States | Details | |
University of California, San Francisco | San Francisco | California | 94143-0372 | United States | Details | |
Massachusetts General Hospital | Boston | Massachusetts | 02113 | United States | Details | |
Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details | |
Memorial Sloan-Kettering Cancer | New York | New York | 10021 | United States | Details | |
Duke University Medical Center | Durham | North Carolina | 27710 | United States | Details | |
UT, MD Anderson Cancer Center | Houston | Texas | 77030 | United States | Details | |
Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | United States | Details |